Compare AbCellera Biologics Inc (ABCL) vs Southern Copper Corp (SCCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Southern Copper Corp — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while Southern Copper Corp trades at $166.52 (market cap $141.63B). The key difference: Southern Copper Corp is far larger — about 60.3× AbCellera Biologics Inc's market cap, and Southern Copper Corp pays a 2.36% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | SCCO | |
|---|---|---|
Market Cap | $2.35B | $141.63B |
Sector | Health | Basic Materials |
52-Week High | $8.12 | $218.85 |
52-Week Low | $2.78 | $90.54 |
Enterprise Value | $1.99B | $143.68B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Southern Copper (SCCO) trades at $169.75, down 1.31% on the day, with a bearish technical signal and mixed analyst sentiment. The stock shows strong fundamentals, including a 34.13% net income margin and robust earnings beats in recent quarters. Revenue growth accelerated to $13.42B in 2025, and the company maintains a solid cash flow profile with $4.75B from operations. Recent corporate actions include a $1.00 dividend and a minor stock split.
SCCO's outlook is supported by copper demand linked to AI infrastructure, but high valuation ratios (P/E 29.44) and bearish technicals pose risks. Analyst consensus is cautious with a $151.21 price target below the current price. Key risks include commodity price volatility and execution challenges in mining operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
